Buying Epoch Biosciences, Nanogen Continues Shifting Market Identity | GenomeWeb

In a move billed as an integration of complementary technology companies, Nanogen plans to acquire Epoch Bioscience in a stock swap worth $58 million. Should shareholders approve the plan, which is expected to close in November or December, the acquisition will cap a difficult year for Nanogen, while pulling several related research products into the struggling company’s tent.

The move should also allow Nanogen to increase its share of the molecular diagnostics and research markets, according to Nanogen and Epoch company officials.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: a sequencing-based screen of Lyme disease-causing pathogen, the range of animals bitten by Anopheles darling mosquitoes in Peru, and more.

An NC State researcher is exploring the use of CRISPR-Cas3 as an anti-microbial, Gizmodo reports.

The Earth BioGenome Project plans to sequence all life on Earth, according to ScienceInsider.

For those who are concerned about Trump administration actions related to science, a new column in Scientific American has suggestions for ways to fight back.